[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.31. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
October 2017

Levodopa and Parkinson Disease—Myths Revisited

Author Affiliations
  • 1Division of Neurology and the Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, University of Malaya, Kuala Lumpur, Malaysia
  • 2Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
JAMA Neurol. 2017;74(10):1270. doi:10.1001/jamaneurol.2017.2560

To the Editor Espay and Lang1 present a thought provoking Viewpoint regarding levodopa therapy in Parkinson disease (PD).1 We respectfully submit that its subtitle “When Clinical Trials Misinform Clinical Practice” is not justified. If levodopa has come into disrepute in the past, and dopamine agonist monotherapy has been left unsupplemented by levodopa for too long, this is not because of misinformation that was provided by the comparative clinical trials themselves, but rather by the inadequate translation of study results into clinical practice.

×